3-fluoro-5-(4-morpholinyl)benzoic acid | 295311-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 3-fluoro-5-(4-morpholinyl)benzoic acid
• 英文别名: 3-fluoro-5-(4-morpholino)benzoic acid；3-fluoro-5-morpholinobenzoic acid；3-fluoro-5-(morpholin-4-yl)benzoic acid；3-fluoro-5-morpholin-4-yl-benzoic acid；3-fluoro-5-morpholin-4-ylbenzoic acid；3-morpholin-5-fluorobenzoic acid；3-Morpholino-5-fluorobenzoic acid
• CAS: 295311-40-9
• 化学式: C₁₁H₁₂FNO₃
• 分子量: 225.22
• InChiKey: IDLGYCXCGFKTDV-UHFFFAOYSA-N

物化性质

• 沸点：
  432.1±45.0 °C(Predicted)
• 密度：
  1.328±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-fluoro-5-(4-morpholinyl)benzoic acid 在 盐酸 、 二苯基膦叠氮化物 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 37.0h， 生成 tert-butyl (2-(4-((3-fluoro-5-morpholinophenyl)carbamoyl)-2,6-dimethylphenoxy)ethyl)carbamate
  参考文献：
  名称：

  Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

  摘要：

  Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.

  DOI：

  10.1021/jm701359z
• 作为产物：
  描述：

  3,5-二氟苯甲酸 在 sodium hydroxide 、 乙醇 、 硫酸 、 水 作用下， 以 二甲基亚砜 为溶剂， 反应 120.0h， 生成 3-fluoro-5-(4-morpholinyl)benzoic acid
  参考文献：
  名称：

  [EN] 5-MORPHOLINYLMETHYLTHIOPHENYL PHARMACEUTIAL COMPOUNDS AS P38 MAP KINASE MODULATORS
  [FR] COMPOSES PHARMACEUTIQUES DE 5-MORPHOLINYLMETHYLTHIOPHENYLE UTILISES COMME MODULATEURS DE LA P38 MAP KINASE

  摘要：

  该发明提供了化合物的结构式(I)或其盐、溶剂合物或N-氧化物，其中：R1和R2相同或不同，每个都选择自氢、饱和的C1-3烃基、卤素和氰基；X选择自C=O、C=S、C(=O)NH、C(=S)NH、C(=O)O、C(=O)S、C(=S)O和C(=S)S；R3选择自芳香族和杂环芳基，每个有5到12个环成员，并且未取代或通过一个或多个在权利要求中定义的取代基R10取代；R4和R5相同或不同，选择自氢和甲基；或者R4和R5中的一个选择自羟甲基和乙基，另一个为氢；R6和R7相同或不同，选择自氢和甲基。该结构式(I)的化合物具有作为p38 MAP激酶和Taf激酶抑制剂的活性。

  公开号：

  WO2005100338A1

文献信息

• Structure-based design, synthesis and biological evaluation of N-pyrazole, N′-thiazole urea inhibitors of MAP kinase p38α
  作者：Matthäus Getlik、Christian Grütter、Jeffrey R. Simard、Hoang D. Nguyen、Armin Robubi、Beate Aust、Willem A.L. van Otterlo、Daniel Rauh

  DOI：10.1016/j.ejmech.2011.11.019

  日期：2012.2

  design, synthesis and biological activity of N-pyrazole, N′-thiazole-ureas as potent inhibitors of p38α mitogen-activated protein kinase (p38α MAPK). Guided by complex crystal structures, we employed the initially identified N-aryl, N′-thiazole urea scaffold and introduced key structural elements that allowed the formation of novel hydrogen bonding interactions within the allosteric site of p38α, resulting

  在本文中，我们介绍了N-吡唑，N'-噻唑-尿素作为p38α促分裂原激活蛋白激酶（p38αMAPK）的有效抑制剂的结构设计，合成和生物学活性。在复杂的晶体结构的指导下，我们采用了最初鉴定的N-芳基，N'-噻唑脲支架，并引入了关键的结构元素，这些元素允许在p38α的变构位点内形成新颖的氢键相互作用，从而产生了有效的III型抑制剂。[4-（3-叔丁基-5-[（（1,3-噻唑-2-基氨基）羰基]氨基} -1 H-吡唑-1-基）-苯基]乙酸18c被发现是该系列中最有效的化合物，可抑制p38α活性，IC 50为135±21 nM。其最接近的类似物，乙基[4-（3-叔丁基-5 - [（1,3-噻唑-2-基氨基）羰基]氨基} -1- ħ -吡唑-1-基）苯基]乙酸甲酯18B，有效抑制HeLa细胞中p38α介导的丝裂原活化蛋白激酶活化蛋白激酶2（MK2）的磷酸化。
• Identification of Novel p38α MAP Kinase Inhibitors Using Fragment-Based Lead Generation
  作者：Adrian L. Gill、Martyn Frederickson、Anne Cleasby、Steven J. Woodhead、Maria G. Carr、Andrew J. Woodhead、Margaret T. Walker、Miles S. Congreve、Lindsay A. Devine、Dominic Tisi、Marc O'Reilly、Lisa C. A. Seavers、Deborah J. Davis、Jayne Curry、Rachel Anthony、Alessandro Padova、Christopher W. Murray、Robin A. E. Carr、Harren Jhoti

  DOI：10.1021/jm049575n

  日期：2005.1.1

  2-amino-3-benzyloxypyridine 1 (IC(50) 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC(50) 35 microM) identified using X-ray crystallographic screening of p38alpha MAP kinase. Using two separate case studies, the article focuses on the key compounds synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate

  我们描述了分子片段2-氨基-3-苄氧基吡啶1（IC（50）1.3毫米）和3-（2-（4-吡啶基）乙基）吲哚2（IC（50）35 microM）的结构指导的优化。通过X射线晶体学筛选p38alpha MAP激酶鉴定出。本文使用两个单独的案例研究，重点讨论了合成的关键化合物，结构-活性关系以及在此优化过程中观察到的结合模式，从而得出了两个有效的先导系列，证明其活性显着提高。我们通过从片段长成相邻的小袋或通过重叠片段的结合来描述化合物的修饰过程，并证明我们已经利用了由Asp168-Phe169-Gly170（DFG）组成的移动保守激活环，
• [EN] 1,4-DISUBSTITUTED NAPHTALENES AS INHIBITORS OF P38 MAP KINASE<br/>[FR] NAPHTALENES DISUBSTITUES EN POSITION 1,4 UTILISES COMME INHIBITEURS DE MAP KINASE P38
  申请人：ARQULE INC

  公开号：WO2006010082A1

  公开（公告）日：2006-01-26

  In general, the present invention relates to compounds capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and methods for treating conditions associated with P38 activity or cytokine activity.

  一般而言，本发明涉及能够抑制P38的化合物，用于体内或体外抑制P38的方法，用于诊断治疗P38和/或细胞因子相关疾病活性的诊断方法，以及用于治疗与P38活性或细胞因子活性相关的疾病的方法。
• [EN] 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES DE 5-AMINO-2-CARBONYLTHIOPHENE UTILISES EN TANT QU'INHIBITEURS DE LA P38 MAP KINASE DANS LE TRAITEMENT DES MALADIES INFLAMMATOIRES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004089929A1

  公开（公告）日：2004-10-21

  The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase; the compound being defined by formula (I): wherein: R1 and R2 are the same or different and each is selected from hydrogen, C1-4 hydrocarbyl, halogen and cyano; X is selected from C=O, C=S, C(=O)NH, C(=S)NH, C(=O)O, C(=O)S, C(=S)O and C(=S)S; R3 is selected from aryl and heteroaryl groups each having from 5 to 12 ring members, the aryl and heteroaryl groups each being unsubstituted or substituted by one or more substituent groups R7 selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra-Rb wherein Ra is a bond, 0, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 7 ring members, and a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1; X1 is 0, S or NRc and X2 is =0, =S or =NRc; Rc is hydrogen or C1-4 hydrocarbyl; R4 is a group YR5 or a group R6; Y is is NH, 0 or S; R5 is selected from (a) carbocyclic and heterocyclic groups having from 3 to 12 ring members; and (b) C1-8 hydrocarbyl groups optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, amino, mono- or di- C1-4 hydrocarbylamino, and carbocyclic and heterocyclic groups having from 3 to 12 ring members, wherein one or more carbon atoms of the C1-8 hydrocarbyl group may optionally be replaced by 0, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1, provided that when Y is 0, a carbon atom adjacent to the group Y is not replaced by 0; and R6 is a heterocyclic group having from 4 to 12 ring members and containing at least one ring nitrogen atom through which R6 is linked to the adjacent carbonyl group; wherein the carbocyclic and heterocyclic groups of substituents R5 and R6 are each unsubstituted or substituted by one or more substituent groups R7 as hereinbefore defined. Also provided are novel compounds, pharmaceutical compositions containing the compounds and methods for their preparation.

  本发明提供了一种化合物的用途，用于制备用于预防或治疗由p38 MAP激酶介导的疾病状态或病况的药物；该化合物由以下式（I）定义：其中：R1和R2相同或不同，每个均选择自氢、C1-4烃基、卤素和氰基；X选择自C=O、C=S、C(=O)NH、C(=S)NH、C(=O)O、C(=O)S、C(=S)O和C(=S)S；R3选择自含有5至12个环成员的芳基和杂环芳基，芳基和杂环芳基未取代或通过一个或多个取代基R7取代，所述取代基R7选择自卤素、羟基、三氟甲基、氰基、硝基、羧基、氨基、具有3至12个环成员的碳环和杂环基；一个基团Ra-Rb，其中Ra为键，0，CO，X1C(X2)，C(X2)X1，X1C(X2)X1，S，SO，SO2，NRc，SO2NRc或NRcSO2；Rb选择自氢、具有3至7个环成员的碳环和杂环基，以及一个C1-8烃基，可选地通过一个或多个取代基选择自羟基、酮基、卤素、氰基、硝基、氨基、单或双C1-4烃基氨基、具有3至12个环成员的碳环和杂环基取代，并且C1-8烃基的一个或多个碳原子可选地被0、S、SO、SO2、NRc、X1C(X2)、C(X2)X1或X1C(X2)X1替代；X1为0、S或NRc，X2为=0、=S或=NRc；Rc为氢或C1-4烃基；R4为一个基团YR5或一个基团R6；Y为NH、0或S；R5选择自（a）具有3至12个环成员的碳环和杂环基；和（b）可选地通过一个或多个取代基选择自羟基、酮基、卤素、氰基、氨基、单或双C1-4烃基氨基、具有3至12个环成员的碳环和杂环基取代的C1-8烃基，其中C1-8烃基的一个或多个碳原子可选地被0、S、SO、SO2、NRc、X1C(X2)、C(X2)X1或X1C(X2)X1替代，但是当Y为0时，与基团Y相邻的碳原子不被0替代；R6为具有4至12个环成员的杂环基，并且通过其中一个环氮原子与相邻的羰基连接；取代基R5和R6的碳环和杂环基各自未取代或通过一个或多个取代基R7取代，如前所述。还提供了新的化合物、含有该化合物的制剂以及其制备方法。
• [EN] THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS<br/>[FR] COMPOSES D'AMIDE THIOPHENIQUE DESTINES A ETRE UTILISES DANS LE TRAITEMENT OU LA PROPHYLAXIE DU CANCER
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2006040569A1

  公开（公告）日：2006-04-20

  The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a cancer or a para-neoplastic effect associated with a cancer, the para-neoplastic effect being other than cachexia, and the compound being a compound of the formula (I), or a salt, solvate or N-oxide thereof, wherein: R1 and R2 are the same or different and each is selected from hydrogen, C1-4 hydrocarbyl, halogen and cyano; X is selected from C=O, C=S, C(=O)NH, C(=S)NH, C(=O)O, C(=O)S, C(=S)O and C(=S)S; R3 is an aryl or heteroaryl group of 5 to 12 ring members optionally substituted by one or more substituent groups R7 wherein R7 is as defined in the claims; R4 is a group YR5 or a group R6; Y is NH, O or S; R5 is selected from (a) optionally substituted carbocyclic and heterocyclic groups having from 3 to 12 ring members; and (b) optionally substituted C1-8 hydrocarbyl 20 groups; and R6 is an optionally substituted heterocyclic group having from 4 to 12 ring members and containing at least one ring nitrogen atom through which R6 is linked to the adjacent carbonyl group.

  该发明提供了一种化合物的用途，用于制造用于预防或治疗癌症或与癌症相关的癌前病变效应的药物，其中癌前病变效应不包括虚弱症，该化合物为式(I)的化合物，或其盐、溶剂合物或N-氧化物，其中：R1和R2相同或不同，每个均选自氢、C1-4烃基、卤素和氰基；X选自C=O、C=S、C(=O)NH、C(=S)NH、C(=O)O、C(=O)S、C(=S)O和C(=S)S；R3为含有5至12个环成员的芳基或杂芳基，可以选择地被一个或多个取代基R7取代，其中R7如索引中定义；R4为一个基团YR5或一个基团R6；Y为NH、O或S；R5选自(a)从3到12个环成员的可选择取代的碳环和杂环基团；以及(b)可选择取代的C1-8烃基基团；R6为一个含有从4到12个环成员的可选择取代的杂环基团，并且至少包含一个环氮原子，通过该环氮原子，R6与相邻的酰基基团连接。